Synthetic Biologics, Inc. (SYN) Reports First Quarter 2013 Financial Results
5/15/2013 7:10:14 AM
More...
|
Synthetic Biologics, Inc. (AEN) Reiterates that the Infectious Disease Collaboration With Intrexon Corporation Remains in Effect
4/22/2013 10:08:43 AM
More...
|
Synthetic Biologics, Inc. (AEN) Reports Year End 2012 Financial Results
4/16/2013 6:43:17 AM
More...
|
Synthetic Biologics, Inc. (AEN) Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple Sclerosis
4/4/2013 12:06:06 PM
More...
|
Synthetic Biologics, Inc. (AEN) to Present at the 25th Annual ROTH Conference
3/12/2013 6:49:49 AM
More...
|
Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics, Inc. (AEN)' Scientific Advisory Board
2/26/2013 12:04:07 PM
More...
|
Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics, Inc. (AEN)'s Scientific Advisory Board
2/26/2013 6:21:42 AM
More...
|
Synthetic Biologics, Inc. (AEN) Reports that Flupirtine Sublicensee, Meda AB (MEDA-A.ST), to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
2/22/2013 8:58:12 AM
More...
|
Synthetic Biologics, Inc. (AEN) to Present at OneMedForum San Francisco 2013
1/7/2013 6:50:42 AM
More...
|
Synthetic Biologics, Inc. (AEN) and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis)
12/21/2012 8:30:37 AM
More...
|
|